You are here: Industry Insights > Pompe disease

News List

Nexviazyme® improves respiration and mobility long-term in Pompe disease patients EuropeanPharmaceuticalReview
February 11, 2022
Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility.
Enzyme Replacement Therapy Approved for Late-Onset Pompe Disease drugs
August 11, 2021
Nexviazyme (avalglucosidase alfa-ngpt) was approved for the treatment of the rare inherited disorder late-onset Pompe disease in patients 1 year of age and older, the U.S. Food and Drug Administration announced Friday.
US FDA approves Nexviazyme for late-onset Pompe disease expresspharma
August 09, 2021
The approval is based on the positive phase-III data demonstrating improvements in key disease burden measures and establishing its safety profile.
FDA Approves Nexviazyme (avalglucosidase alfa-ngpt) for Late-Onset Pompe Disease drugs
August 09, 2021
The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder.